Virax Biolabs Group Limited
VRAX
Last
$1.87
Day
-6.0%
1y
-88.3%
5y
-100.0%
52w
-90.9%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
—
EMA 21
2.32
EMA 50
2.67
EMA 200
6.20
20d high
-40.4%
5y high
-100.0%
5y range
0th
Positions held
Your positionsVRAX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-30
Hold
avoid
Signal
Strong Sell
Target
$2.55
Stop
$1.52
Stop distance
18.7%
Target vs last
+36.4%
Fundamentals
| Market cap | $2.68M | Enterprise value | -$5.19M | Trailing P/E | — | Forward P/E | -0.33 |
| PEG | — | Price / book | 0.15 | Beta | 1.39 | Dividend yield | 0.00% |
| Revenue growth | 6.8% | Earnings growth | — | Gross margin | 61.9% | Operating margin | -352.6% |
| Profit margin | 0.0% | ROE | -78.6% | ROA | -54.2% | Debt / equity | 0.06 |
| Current ratio | 9.97 | Free cash flow | -$3.48M | Analyst recommendation | none | Mean target | — |
| 52w high | $21.75 | 52w low | $1.83 |
Quarterly
No data yet.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.2M | $0.0M | — |
| Op margin | -51515.2% | -95984.9% | -3922.4% | -66963.7% | — |
| Net income | -$5.0M | -$6.1M | -$6.7M | -$5.5M | — |
| Gross margin | 61.9% | -838.2% | 32.3% | -15.9% | — |
| Gross profit | $0.0M | -$0.1M | $0.1M | -$0.0M | — |
| Operating income | -$6.4M | -$6.1M | -$6.1M | -$5.7M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-20 · Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution
2026-07-20 · Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-07-13 · Virax Biolabs enters immune profiling product supply deal with Fosun
2026-07-13 · Virax Biolabs enters immune profiling product supply deal with Fosun
Price (daily)
Full chart · RSI · MACD · patternsVRAX · daily-20.4% over 13 sessions
Close EMA21 EMA50 EMA200